The Latest Breaking News from APGE

The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

Barchart · Jun 22

Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing

Apogee Therapeutics (NASDAQ:APGE) executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone. Speaking at a Jefferies-hosted

MarketBeat · Jun 4

Dow Adds 631 Points as Hormuz Vise Eases: Stock Market Today

Price action up and down and all over the world is being driven by the president of the United States in unprecedented ways these days.

Kiplinger · Mar 23